Swiss National Bank
IMVT icon

Swiss National Bank’s Immunovant IMVT Stock Holding History

Swiss National Bank’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.11M Sell
132,700
-26,700
-17% -$813K ﹤0.01% 1440
2026
Q1 		$3.96M Buy
159,400
+1,100
+0.7% +$28.5K ﹤0.01% 1482
2025
Q4 		$4.02M Buy
158,300
+25,700
+19% +$573K ﹤0.01% 1476
2025
Q3 		$2.14M Buy
132,600
+2,800
+2% +$45.3K ﹤0.01% 1824
2025
Q2 		$2.08M Sell
129,800
-1,800
-1% -$27.2K ﹤0.01% 1796
2025
Q1 		$2.25M Buy
131,600
+30,800
+31% +$644K ﹤0.01% 1692
2024
Q4 		$2.5M Buy
100,800
+1,200
+1% +$34K ﹤0.01% 1729
2024
Q3 		$2.84M Hold
99,600
– – ﹤0.01% 1656
2024
Q2 		$2.63M Hold
99,600
– – ﹤0.01% 1673
2024
Q1 		$3.22M Hold
99,600
– – ﹤0.01% 1568
2023
Q4 		$4.2M Sell
99,600
-29,500
-23% -$1.09M ﹤0.01% 1392
2023
Q3 		$4.96M Buy
129,100
+15,700
+14% +$355K ﹤0.01% 1285
2023
Q2 		$2.15M Buy
113,400
+29,800
+36% +$556K ﹤0.01% 1839
2023
Q1 		$1.3M Sell
83,600
-9,900
-11% -$172K ﹤0.01% 2092
2022
Q4 		$1.66M Sell
93,500
-1,600
-2% -$20.1K ﹤0.01% 2019
2022
Q3 		$531K Hold
95,100
– – ﹤0.01% 2544
2022
Q2 		$371K Hold
95,100
– – ﹤0.01% 2677
2022
Q1 		$524K Buy
95,100
+6,400
+7% +$39.9K ﹤0.01% 2597
2021
Q4 		$756K Buy
88,700
+13,100
+17% +$108K ﹤0.01% 2566
2021
Q3 		$657K Hold
75,600
– – ﹤0.01% 2535
2021
Q2 		$799K Sell
75,600
-1,900
-2% -$26.5K ﹤0.01% 2546
2021
Q1 		$1.24M Hold
77,500
– – ﹤0.01% 2267
2020
Q4 		$3.58M Buy
77,500
+3,300
+4% +$153K ﹤0.01% 1567
2020
Q3 		$2.61M Buy
74,200
+22,600
+44% +$680K ﹤0.01% 1579
2020
Q2 		$1.26M Buy
+51,600
New +$1.11M ﹤0.01% 1966

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Swiss National Bank's IMVT Position: Q2 2026 in Review

Swiss National Bank reduced its Immunovant (IMVT) stake by 17% in Q2 2026, selling an estimated $813K and leaving 132,700 shares worth $5.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1440.

Swiss National Bank first reported a position in IMVT in Q2 2020 and has held it in 25 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Swiss National Bank held 132,700 shares of Immunovant worth $5.11M as of Q2 2026.
  • Swiss National Bank sold 26,700 Immunovant shares in Q2 2026, an estimated $813K.
  • Immunovant made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1440 holding.
  • Swiss National Bank first reported a position in Immunovant in Q2 2020 and has held it in 25 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.